STOCKWATCH: Missing the point
This article was originally published in Scrip
Executive Summary
As investors in life science stocks, and biotechnology companies in particular, suffered another week of significant losses there are still voices of denial from the analyst community that have completely missed the point of what the market is telling them. The generalist investor is selling out of biotech and nothing can stop the exit.
You may also be interested in...
Stock Watch: The Rise Of Biotech Platforms
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.
Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness
Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.
Stock Watch: Biopharma Caught In US Government Anti-Bundling Drive
Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.